Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. - Wikidata - wikimedia - TriplyDB

Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.

Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.

http://www.wikidata.org/entity/Q50456063

about

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer Medical interventions for the prevention of platinum-induced hearing loss in children with cancer Medical interventions for the prevention of platinum-induced hearing loss in children with cancer Cardioprotective interventions for cancer patients receiving anthracyclines Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity.Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.Drug-induced acute kidney injury in children The role of antioxidants in the era of cardio‑oncology.Late Cardiotoxicity: Issues for Childhood Cancer Survivors.Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.Extraskeletal osteosarcoma of the orbit: A clinicopathologic case report and review of literature.Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity.Anticancer effects of 10-hydroxycamptothecin induce apoptosis of human osteosarcoma through activating caspase-3, p53 and cytochrome c pathways.

P2860

Q24194929-24671961-E030-4205-8A66-235285D017E1 Q24197545-014B1308-86E4-494E-A5F1-A7FE6DDD9F49 Q24197812-0EBBBAB6-6AC6-4823-99A1-20B8D854C2DD Q24236069-E316CD94-478E-4E81-B1A3-43CD4D46308D Q24236338-DFEA3BC2-4C6A-4165-8DB7-E4EC9D0EB145 Q24615296-2D0A4B6E-AC96-462A-92D2-B42B13006B17 Q26742059-9626C1FE-C9A2-4653-8009-937C73E50D90 Q27335267-D80B6DB7-A89F-4F8E-9F0F-C9BD0098C175 Q30578179-D1A7A6B7-532E-493D-B6E9-61C80B24D291 Q33619867-BA99619C-53C9-431B-A27E-54CFCD57A4CA Q35019735-F10C2428-B09A-4CDD-B886-DF89A3C3C260 Q35562745-7D451238-398B-4ED0-A06E-7F29912800C7 Q36057728-B9E980F3-22B4-4448-9DC0-AFA2836AC7B9 Q36125552-71790FAB-F643-4A50-A7E1-0E818E8D5B13 Q37626273-BE1149D9-621E-4C8C-ACC6-C8B179D31424 Q38845457-EA0C632A-7EA1-4772-80E7-96DD5408329E Q38964704-350A8F22-6271-41A0-895B-FFFB00AE990F Q39010531-91FB38E6-B6AF-48A3-B066-106BDB547FBA Q46253112-36F171DE-6441-4E8E-99CA-7A1676144CCE Q49422596-0A506AFB-B1D9-4596-A08D-7FE8166F3BA3

P2860

Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.

http://www.wikidata.org/entity/Q50456063

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Toxicity prevention with amifo ...... ith cisplatin and doxorubicin.

@en

Toxicity prevention with amifo ...... ith cisplatin and doxorubicin.

@nl

type

label

Toxicity prevention with amifo ...... ith cisplatin and doxorubicin.

@en

Toxicity prevention with amifo ...... ith cisplatin and doxorubicin.

@nl

prefLabel

Toxicity prevention with amifo ...... ith cisplatin and doxorubicin.

@en

Toxicity prevention with amifo ...... ith cisplatin and doxorubicin.

@nl

P1433

Q50456063-32B0AA5E-69EA-4288-83F0-C97529A31438

P1476

Q50456063-974583F5-84DC-4D4E-970C-88F5850EA519

P2093

Q50456063-1B813788-F221-4483-90F0-EDFD7A773532

Q50456063-286A72B1-7509-4D83-B2DA-99F0E3DD53E4

Q50456063-2906C228-2D38-45B5-ADB9-53111C3F7FA4

Q50456063-5D008BAC-8C8A-40EA-9566-584267217E2F

Q50456063-8A095166-4046-4ACF-933E-960713C3FD53

Q50456063-D17B6724-9C6F-42FE-91F3-DC5A3151F662

P2860

Q50456063-13E1FFD2-2EFB-46FB-8D9D-25F46FFBBD61

Q50456063-20A237FC-BD48-4CCB-8826-390B844FBB91

Q50456063-347D0D0E-4817-499D-B617-7962F4BBC64B

Q50456063-3A949798-EC91-49CB-8E94-FCE94C200EF9

Q50456063-67088BB4-AAE2-4A00-B098-0F132F2C9ECA

Q50456063-9E57B7BF-28BB-4590-9C01-2FED7C5EFF03

Q50456063-CC983764-A277-4CB5-B644-7BD5A8722B80

P304

Q50456063-6AEB45D8-AEFE-4902-A377-5F7DBDB3398A

P31

Q50456063-B971C6E3-E878-449F-AEF2-72070E0853A3

P356

Q50456063-08EB9F80-66AC-4435-99E6-EA9F0817307A

P433

Q50456063-784B99BB-AF98-489E-A5B4-16669FFB4D04

P478

Q50456063-DEC7BDE4-A6C5-4030-949D-8996B2A353F1

P577

Q50456063-DE8791DF-33BB-4C47-84BF-13B73CF3B794

P698

Q50456063-D9F5CF6F-7DF8-4376-804D-0F0361F58843

P356

08880010701451244

P1433

Pediatric Hematology and Oncology

P1476

Toxicity prevention with amifo ...... ith cisplatin and doxorubicin.

@en

P2093

Alejandro Mohar-Betancourt

http://www.w3.org/2001/XMLSchema#string

Armando Martínez-Avalos

http://www.w3.org/2001/XMLSchema#string

Aurora Medina-Sansón

http://www.w3.org/2001/XMLSchema#string

Guadalupe Guerrero-Avendaño

http://www.w3.org/2001/XMLSchema#string

Martha Zapata-Tarrés

http://www.w3.org/2001/XMLSchema#string

Sergio Gallegos-Castorena

http://www.w3.org/2001/XMLSchema#string

P2860

Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.

Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.

Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).

Use of amifostine in the therapy of osteosarcoma in children and adolescents.

Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.

WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.

Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.

P304

403-408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/08880010701451244

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17710657

http://www.w3.org/2001/XMLSchema#string